ViroPharma Incorporated (VPHM)

[surf1944]

3:42AM ViroPharma receives orphan drug designation for Maribavir In Europe (VPHM) 27.79 : Co announces that the European Commission has granted orphan drug designation for maribavir for treatment of cytomegaloviral disease in patients with impaired cell mediated immunity. The "Orphan Medicinal Product Designation" is designed to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases identified as "life-threatening or chronically debilitating" conditions. ViroPharma has previously received orphan drug designation for maribavir in the United States for treatment of clinically significant cytomegalovirus viremia and disease in at-risk patients.